ArticleFrontiers in neurology
Association of neurogenic orthostatic hypotension with cognitive decline in Parkinson's disease: a longitudinal cohort study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stage-dependent clinical burden in hospitalized Parkinson's disease with a positive bedside orthostatic hypotension screen: a retrospective cross-sectional analysis.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neurogenic orthostatic hypotension (nOH), a common non-motor feature of Parkinson's disease (PD), is defined as a sustained drop in blood pressure (BP) upon standing due to autonomic dysfunction. Although prior studies support an association between nOH and cognitive impairment, its longitudinal impact on cognitive decline in PD remains insufficiently explored. We aimed to determine to what extent baseline nOH is associated with an accelerated decline in global and exploratory domain-specific cognitive functions. Methods: A retrospective longitudinal cohort study was conducted using clinical data from patients with PD evaluated at the University of California San Diego movement disorders clinics between 2012 and 2024. Participants were classified as having nOH (nOH+) or without nOH (nOH-) based on initial orthostatic BP measurements (≥20 mmHg systolic BP and/or ≥10 mmHg diastolic BP reduction within 3 minutes of standing, with a blunted heart rate response [ΔHR/ΔSBP] < 0.5 bpm/mmHg). Cognitive performance was assessed using the Montreal Cognitive Assessment (MoCA), including total scores and domain-specific subscores. Longitudinal changes in cognitive function were modeled using linear mixed-effects models, adjusting for time, nOH status, age, sex, and their interaction. Motor and non-motor symptom progression was evaluated using the MDS-UPDRS Parts I-III. Results: Patients with nOH at the first visit showed faster decline in total MoCA scores (Interaction Discussion: In this single-center, real-world retrospective cohort, the presence of baseline nOH was associated with a more rapid decline in cognitive function. These findings highlight the potential importance of early autonomic assessment in PD and warrant further investigation in larger, multi-center studies to determine generalizability and to better understand the underlying mechanisms contributing to cognitive deterioration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.